doi:10.19982/j.issn.1000-6621.20240375

Abstract

CLC Number:

R563

Figures/Tables 1

References 21

[1]	Kumar K, Ponnuswamy A, Capstick TG, et al. Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemio-logy, diagnosis and multidisciplinary management. Clin Med (Lond), 2024, 24(1):100017. doi:10.1016/j.clinme.2024.100017.
[2]	Kumar K, Kon OM. Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease. Microorganisms, 2021, 9(11):2220. doi:10.3390/microorganisms9112220.
[3]	Cowman S, van Ingen J, Griffith DE, et al. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J, 2019, 54(1):1900250. doi:10.1183/13993003.00250-2019.
[4]	Takeda K, Imamura Y, Takazono T, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol, 2016, 54(2):120-127. doi:10.1093/mmy/myv093. URL pmid: 26531100
[5]	郭明日, 张丽霞, 周洪经, 等. 非结核分枝杆菌肺病患者下呼吸道感染病原菌分布及耐药性分析. 中华医院感染学杂志, 2016, 26(20):4641-4644. doi:10.11816/cn.ni.2016-160166.
[6]	罗春明, 黄业伦, 邹桂敏. 光镜观察液体培养基中结核与非结核分枝杆菌生长形态的比较. 广东医科大学学报, 2007, 25(2):192-193. doi:10.3969/j.issn.1005-4057.2007.02.032.
[7]	王敬, 初乃惠, 段鸿飞, 等. 鸟胞内分枝杆菌复合群肺病患者23例临床分析. 中华临床医师杂志(电子版), 2012, 6(24):8126-8129. doi:10.3877/cma.j.issn.1674-0785.2012.24.107.
[8]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
[9]	Koyama K, Ohshima N, Suzuki J, et al. Evaluation of clinical characteristics and prognosis of chronic pulmonary aspergillosis depending on the underlying lung diseases: Emphysema vs prior tuberculosis. J Infect Chemother, 2015, 21(11):795-801. doi:10.1016/j.jiac.2015.08.006.
[10]	冯春来, 施毅. 肺曲霉球诊治进展. 中国呼吸与危重监护杂志, 2014, 13(4):4. doi:10.7507/1671-6205.2014105.
[11]	师凌昊, 程菲, 郭英华, 等. 非结核分枝杆菌肺病191例临床特征. 中华医院感染学杂志, 2023, 33(24):3742-3747. doi:10.11816/cn.ni.2023-231054.
[12]	Nakamoto K, Takayanagi N, Kanauchi T, et al. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med, 2013, 52(7):727-734. doi:10.2169/internalmedicine.52.9142.
[13]	李春梅, 南岩东, 李王平, 等. 病理确诊的慢性肺曲霉菌病的临床特点分析. 中华肺部疾病杂志(电子版), 2019, 12(2): 202-204. doi:10.3877/cma.j.issn.1674-6902.2019.02.015.
[14]	Patterson KC, Strek ME. Diagnosis and treatment of pulmonary aspergillosis syndromes. Chest, 2014, 146(5):1358-1368. doi:10.1378/chest.14-0917. URL pmid: 25367472
[15]	Passera E, Rizzi A, Robustellini M, et al. Pulmonary aspergilloma: clinical aspects and surgical treatment outcome. Thoracic Surg Clin, 2012, 22(3):345-361. doi:10.1016/j.thorsurg.2012.04.001.
[16]	Moodley L, Pillay J, Dheda K. Aspergilloma and the surgeon. J Thorac Dis, 2014, 6(3):202-209. doi:10.3978/j.issn.2072-1439.2013.12.40. URL pmid: 24624284
[17]	Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg, 2009, 138(4):820-825. doi:10.1016/j.jtcvs.2009.01.019. URL pmid: 19660294
[18]	Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J, 2016, 47 (1): 45-68. doi:10.1183/13993003.00583-201. URL pmid: 26699723
[19]	汤中文, 倪正义, 周密, 等. 慢性肺曲霉菌病的外科治疗分析. 临床外科杂志, 2018, 26(2):108-110. doi:10.3969/j.issn.1005-6483.2018.02.009.
[20]	Farid S, Mohamed S, Devbhandari M, et al. Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence—a National Centre’s experience. J Cardiothorac Surg, 2013, 8:180. doi:10.1186/1749-8090-8-180.
[21]	刘恒, 邝爱玲, 陈日垦, 等. 慢性肺曲霉病的诊治进展. 国际呼吸杂志, 2016, 36(24):1910-1913. doi:10.3760/cma.j.issn.1673-436X.2016.24.018.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[2]	Zhu Jiankun, Meng Qian, Kong Kangbao, Jin Feng. The value of pneumonectomy in the treatment of pulmonary mucormycosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 274-281.
[3]	Fu Ying, Xiong Yangyang, Fang Si, Li Chuanxiang, Guo Hongrong. The research progress on the relationship between serum albumin and its derivative biomarkers and chronic obstructive pulmonary disease [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 231-236.
[4]	Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65.
[5]	Liang Feng, Liu Deqing, Chen Hua, Chen Pinru, Tan Yaoju, Hu Jinxing, Zhang Danni, Xu Liuqing. Epidemiological characteristics of non-tuberculous mycobacterial disease in Guangzhou [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1373-1379.
[6]	Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076.
[7]	Tan Shouyong. Research progress on comprehensive treatment beyond antibiotic therapy for nontuberculous mycobacterium pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 967-970.
[8]	Yang Chengqing, Chen Shufang, Mei Chunlin, Cao Tanze, Feng Wei, Liu Xiuping, Xu Wenjing, Du Ronghui. Clinical characteristics of 220 cases of pulmonary tuberculosis combined with chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 770-777.
[9]	Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829.
[10]	Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755.
[11]	He Xiangrong, Chen Hua, Chen Pinru, Liang Feng, Ren Huili, Zhu Jialou, Hu Jinxing, Tan Yaoju. A case report and literature review of Mycobacterium asiaticum pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 763-769.
[12]	Han Wenya, Zhou Yangyu, Wang Meifang, Xue Xinying. Progress in clinical diagnosis and treatment of pulmonary cryptococcosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 830-838.
[13]	Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698.
[14]	Zhou Xue, He Fang, Di Yicheng, Zhang Zheng, Liu Ju. Analysis of risk factors of respiratory failure in elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 357-361.
[15]	. [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1112-1116.